Clinical Trials Logo

Filter by:
NCT ID: NCT05726110 Recruiting - Clinical trials for Relapsed or Refractory Acute Myeloid Leukemia

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Start date: January 29, 2023
Phase: Phase 3
Study type: Interventional

This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

NCT ID: NCT05725915 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC

Start date: December 1, 2022
Phase:
Study type: Observational

The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed. This study is a real world study, aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitor(ICI) combined with chemotherapy, and to explore the correlation and predictive value of each single biomarker, so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment.

NCT ID: NCT05725590 Recruiting - Pancreatic Fistula Clinical Trials

A Multicenter Randomized Controlled Study of External Pancreatic Duct Stents in Pancreaticoduodenectomy

Start date: February 2, 2023
Phase: N/A
Study type: Interventional

The prognostic value of external vs internal pancreatic duct stents after pancreaticoduodenectomy remains controversial. This study aimed to evaluate the benefits of external and internal stents using the Updated Alternative Fistula Risk Score in both high-risk and low-risk patients with regard to the incidence of clinically relevant postoperative pancreatic fistula.

NCT ID: NCT05725096 Recruiting - Clinical trials for Adherence, Medication

Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population

RESPECT2
Start date: June 28, 2023
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.

NCT ID: NCT05724732 Recruiting - Solid Tumor Clinical Trials

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

This study is a single-center, single-arm phase I clinical trial. A total of 24~26 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study. An "autologous tumor-infiltrating lymphocyte therapy" dosing regimen consisting of lymphodepleting chemotherapy (FC regimen: cyclophosphamide + fludarabine), infusion of autologous tumor-infiltrating lymphocyte injection, and interleukin-2 injection will be used.The study process is divided into: screening period, sampling and production period, clearing and chemotherapy period, treatment and observation period, and follow-up period

NCT ID: NCT05724355 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice.

NCT ID: NCT05724342 Recruiting - Stroke, Ischemic Clinical Trials

Tenecteplase REperfusion in Acute Ischemic sTroke Registry(TREAT)

Start date: February 15, 2023
Phase:
Study type: Observational

The aim of the study was to establish tenecteplase thrombolysis database and to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients.

NCT ID: NCT05724329 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinomas

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Start date: February 5, 2023
Phase: Phase 2
Study type: Interventional

The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who are about to undergo surgery.

NCT ID: NCT05724290 Enrolling by invitation - Rhinitis, Allergic Clinical Trials

Mechanism of EGR2 in Allergic Rhinitis

Start date: January 30, 2023
Phase: Phase 1
Study type: Interventional

EGR2 may be a target for the treatment of nasal polyps.

NCT ID: NCT05724199 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

ROCKET-SHUTTLE
Start date: February 21, 2023
Phase: Phase 3
Study type: Interventional

The coprimary objectives of the study are to: - evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™). - evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI).